An antibody for treating benign prostatic hyperplasia and its application

By developing the nanobody AbG1 that targets the GnRH receptor, the binding of endogenous GnRH to the receptor is blocked, solving the problems of drug side effects and surgical risks in the treatment of benign prostatic hyperplasia, and achieving a highly effective and low-toxicity treatment effect.

CN122302065APending Publication Date: 2026-06-30THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
Filing Date
2026-05-12
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Current technologies lack highly effective and low-toxicity drugs for treating benign prostatic hyperplasia (BPH). Traditional drugs have significant side effects or are not very effective, surgical treatment carries the risk of trauma, and the development of nanobodies targeting GnRH receptors is very difficult.

Method used

A nanobody AbG1 targeting the GnRH receptor was developed. It was constructed using alpaca immune and phage display libraries. High-affinity and high-specificity nanobodies were screened to block the binding of endogenous GnRH to the receptor, inhibit LH/FSH secretion, and reduce testosterone and DHT levels.

Benefits of technology

AbG1 significantly reduces the prostate index, improves symptoms of benign prostatic hyperplasia, has significant in vivo therapeutic effects, and has a small molecular weight, good tissue penetration, easy and efficient expression, and controllable side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122302065A_ABST
    Figure CN122302065A_ABST
Patent Text Reader

Abstract

This invention relates to the field of biomedicine, specifically disclosing an antibody for treating benign prostatic hyperplasia (BPH) and its applications. The antibody is a nanobody containing a complementary determinant region (CDR) sequence as shown in SEQ ID NO:5. This invention provides a method for preparing the antibody and demonstrates that it effectively antagonizes the binding of GnRH to GnRHR, thereby inhibiting cAMP production mediated by the GnRH signaling pathway and reducing the levels of testosterone, dihydrotestosterone, and luteinizing hormone. In vivo pharmacodynamic experiments show that the antibody provided by this invention can significantly improve the prostate weight / body weight ratio in a rat model of benign prostatic hyperplasia, exhibiting a good therapeutic effect on BPH and providing a new candidate drug for the clinical treatment of BPH.
Need to check novelty before this filing date? Find Prior Art